Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ... OH, USA, won the Outstanding New Product Award presented ... Biological and Environmental Repositories (ISBER) at their annual meeting ... annually, recognizes the company’s development and introduction of the ... award was presented to Global Cooling’s CEO Neill Lane ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm Clinic ... about Appearance Medicine . Although Dr. Hart regularly teaches ... to lecture in China, and quite a different experience it ... 12 and 7 million people respectively. Interest in cosmetic facial ... in time. As Dr. Hart passed through the Fuzhou airport ...
(Date:5/16/2013)... 2013 Kitware , a ... announces new Phase II SBIR funding from the ... of an open-source, high performance computing (HPC) simulation ... enables researchers to select only the toolkits and ... computation, or analysis tasks. , Manufacturers increasingly ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
Breaking Biology Technology:Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... DR and Data Management Systems Spurs ... Forty-Five Percent Growth for Company, SANTA CLARA, ... digital radiography (DR), PACS (Picture Archiving and,Communications System) and Practice ... grew 45 percent,to surpass $35 million for the year ending ...
... Fla., Feb. 14 GeoPharma, Inc. (Nasdaq:,GORX) announced ... quarter,representing more than a 200% increase in sales ... and nine month periods ending,December 31, 2007., ... results for the,third quarter of our 2008 fiscal ...
... -- Shenzhen Beike,Biotechnology Co., Ltd. ( http://www.beikebiotech.com ... umbilical cord stem cells to successfully treat a ... Lord Mayor of,Manchester, has returned today to the ... and life-threatening condition known as,cerebellar atrophy. As the ...
Cached Biology Technology:Eklin Medical Reports Record Revenues for 2007 2Eklin Medical Reports Record Revenues for 2007 3GeoPharma Announces Record Revenues in Third Quarter Results 2GeoPharma Announces Record Revenues in Third Quarter Results 3GeoPharma Announces Record Revenues in Third Quarter Results 4GeoPharma Announces Record Revenues in Third Quarter Results 5GeoPharma Announces Record Revenues in Third Quarter Results 6Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 2Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 3
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
(Date:5/18/2013)... presented at Digestive Disease Week (DDW) explores new ... lifestyle. , Individuals suffering from Crohn,s disease ... and poor quality of life. These symptoms can ... randomized, double blind, placebo-controlled study found for the ... significant relief of these symptoms. , "Our ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3
... foundation of biological inheritance is DNA replication a tightly ... of thousands of different sites across the genome. If that ... be cells with missing or extra genetic material, a hallmark ... cancers. University of North Carolina School of Medicine scientists ...
... 2012) -- Scientists at Weill Cornell Medical College have ... -- exerts a spigot-like function, controlling the volume of ... of brain neurons. The study, published online in ... other through these signals, relaying thoughts, feelings and action, ...
... and a carnivorous plant, the ants contribute to both prey ... amounts of nutrients derived from their wastes. This offers the ... in the open access journal PLoS ONE ... grows in the nutrient-poor peatswamp forests of Borneo but bears ...
Cached Biology News:DNA replication protein also has a role in mitosis, cancer 2New study discovers powerful function of single protein that controls neurotransmission 2New study discovers powerful function of single protein that controls neurotransmission 3New study discovers powerful function of single protein that controls neurotransmission 4